1 Title

Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study

4

5 Authors: Gil Verschelden^{1*}, Maxim Noeparast^{2,3*}, Maryam Noparast⁴, Maïlis
6 Lauwers⁵, Charlotte Michel⁶, Frédéric Cotton⁷, Cleo Goyvaerts⁷, Maya Hites¹.

7 * Shared first authors

8

1. Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles (CUB), 9 Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium 10 11 2. Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University, 35043 Marburg, Germany 12 3. Fonds Wetenschappelijk Onderzoek (FWO) – Vlaanderen 13 4. Department of Urologic Sciences, University of British Columbia, Vancouver, 14 BC, Canada. 15 5. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de 16 17 Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, 18 Belgium 6. Department of Microbiology, Laboratoire Hospitalier Universitaire de 19 Bruxelles (LHUB-ULB), Brussels, Belgium 20 7. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de 21 Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, 22 23 Belgium 8. Laboratory for Molecular and Cellular Therapy (LMCT), Vrije Universiteit 24 Brussel (VUB), 1090 Brussels, Belgium 25

27 **Corresponding authors:** Gil.Verschelden@erasme.ulb.ac.be,

- 28 Maxim.Noeparast@staff.uni-marburg.de, and <u>Maya.Hites@erasme.ulb.ac.be</u>
- 29

30 Abstract

31 Deficiency of the element zinc is associated with cytokine releasing syndrome (CRS)

32 and the related acute respiratory distress syndrome as well as impaired antiviral

response. Similar complications associate with severe SARS-CoV-2.

34

We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hopital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.

One hundred and thirty-nine eligible patients were included between May 2020 and
November 2020 (median age of 65 years [IQR, 54 to 77]).

Our cohort's mean plasma zinc concentration was 56.2 μ g/dL (standard deviation [SD], 14.8) compared to 75.7 μ g/dL (SD = 18.9 μ g/dL) in the retrospective non-COVID-19 control group (N = 1513; *P* <.001). Markedly, the absolute majority of patients (96%) were zinc deficient (<80 μ g/dL).

The mean zinc concentration was lower in patients with CRS compared to those without CRS (-5 μ g/dL; 95% CI, -10.5 to 0.051; *P* = 0.048).

Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; P = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and

53 predicting outcomes in patients diagnosed with COVID-19 at the early stage of the

54 disease.

- 55
- 56 Keyword: SARS-CoV-2, COVID-19, Zinc, cHIS, inflammation
- 57

58 Main text

59 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with
significant mortality and morbidity in a subgroup of patients who develop cytokine
release syndrome (CRS) and the related acute respiratory distress syndrome
(ARDS)^{1,2}.

64

Zinc is the second most abundant common trace mineral in humans, yet ~20% of the 65 global population is estimated to suffer from different degrees of zinc deficiency³. 66 Precedent evidence suggests that zinc deficiency also can be associated with lung-67 68 damaging complications such as ARDS^{4,5} as well as impaired antiviral response^{3,6–9}. For instance, zinc deficiency has shown to be associated with excessive TNF-a and IL-69 6 activity, factors known to have a significant role in CRS^{9,10}. 70 However, the zinc status and its association with SARS-CoV-2 remains unknown. 71 72 Herein, we designed a study to determine the zinc status, explored the association 73 74 between the plasma zinc concentration, the development of CRS, and the clinical 75 outcomes in hospitalized COVID-19 patients. 76

77 Methods

We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) between May 2020 and November 2020. Consecutive hospitalized adult patients with PCR-confirmed SARS-CoV-2 infection were enrolled after obtaining informed consent. We performed clinical and laboratory assessments within 72 hours of admission. An atomic absorption spectroscopy technique was used to measure zinc concentrations in the plasma¹¹.

Plasma zinc concentrations of COVID-19 patients were compared with our retrospective cohort of 1513 adult non-COVID-19 patients whose plasma zinc was previously measured in our center. The patients were selected regardless of gender or comorbidity during 2018.

89

90 The severity of COVID-19 was assessed daily during the course of hospitalization
91 using the WHO 10-point system¹².

Individual inflammatory parameters were assessed and summed on the day of 92 93 patients' study inclusion according to an additive six-point clinical scale, developed 94 and validated by Webb et al.¹³, to determine the presence and severity of COVID-19associated hyperinflammatory syndrome (cHIS)¹¹. Although the authors reported an 95 excellent discrimination¹⁴ of the maximum daily cHIS score for both in-hospital 96 mortality and mechanical ventilation, external validation was still lacking. As part of 97 98 this study, we independently evaluated the relevance of the cHIS scoring system and determined the best cut-offs in our cohort. 99

100

101 We defined the clinical outcomes as the length of hospitalization, the incidence of 102 mechanical ventilation (including invasive and non-invasive ventilation), and

mortality. We recorded the outcomes with a follow-up of 90 days from hospitaladmission.

105

106 Baseline characteristics and patients' outcomes

107 One hundred and thirty-nine eligible patients were included. The patient 108 characteristics and laboratory assessments are summarized in Table and Figure 1.

109

110 The participants were predominantly male (91/139, 65%) with a median age of 65 111 years (interquartile range [IQR], 54 to 77). Ninety-six patients (69%) had two or 112 more comorbidities. The median body mass index (BMI) was 27 kg/m² and 93/135 113 (69%) patients had a BMI >25 kg/m², among which 41/135 (30%) patients were 114 considered obese (BMI >30 kg/m²). The median time from symptoms onset to 115 inclusion was eight days (IQR, 6 to 12).

The median worst daily WHO severity score was 4 (IQR, 4 to 6). Forty-two patients
(30%) required mechanical ventilation or deceased during their hospitalization
(WHO score >5, severe COVID-19)¹⁰.

Nineteen patients (14%) were admitted to the intensive care unit (ICU) during their
hospital stay. Twenty patients (14%) deceased within 90 days of admission, of whom
seven (35%) had been admitted to ICU.

122

123 Zinc status and its association with patients' outcomes

The mean plasma zinc concentration in our cohort was 56.2 μ g/dL (SD = 14.8) compared to 75.7 μ g/dL (SD = 18.9 μ g/dL) in the control group. An unpaired t-test with unequal variance (Welch's t-test) confirms that this difference is significant (*P* <.001).

128 Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient 129 (<80µg/dL).

130

We observed that the plasma zinc concentration is weakly but significantly correlated (rho = -0.19; P = 0.022) with the length of hospital stay. However, the plasma zinc concentration was not significantly associated with the risk of mortality or morbidity (Table 2b). Still, the mean plasma zinc levels were systematically lower in mechanically ventilated- compared to non-mechanically ventilated COVID-19 cases (-5.23 µg/dL; 95% confidence interval [CI], -10.57 to 0.13; P = 0.058), and in dead compared to surviving participants (-6. 68 µg/dL; 95% CI, -13.68 to 0.33; P = 0.065).

138

External validation of the cHIS score as the measure of inflammatory status

The area under the receiver operating characteristic curve (AUROC) for mechanical ventilation and mortality was 0.687 and 0.674, respectively, which indicates a lack of discrimination capacity (AUC \leq 0.7¹⁴). Nevertheless, according to the results of the Hosmer-Lemeshow goodness of fit test¹⁴, the score demonstrated a good calibration (p-value > 0.05), with p-values of 0.681 and 0.649 for mechanical ventilation and mortality, respectively.

147 Next, we aimed to identify a cHIS cut-off, which corresponds to CRS, to define a 148 binary (low- and high-risk for poor outcome) patient group regarding inflammatory 149 status. Our data corroborate with the cut-off suggested by Webb et al.¹¹, 150 demonstrating the best performance (Youden's J statistic closest to one) at a 151 threshold of $\geq 2^{15}$.

152 In our cohort, 74/134 (55%) patients had a cHIS score ≥ 2 . Importantly, greater 153 proportions of these cases needed mechanical ventilation (30/74, 40%) and died

(16/74, 22%) compared to patients with cHIS scores < 2 (11/60, 18%; P = 0.006) and
(4/60, 7%; P = 0.013) respectively.

156

157 Although our results support the association of CRS with both severe COVID-19 and mortality, unlike Webb et al., we were not able to demonstrate an excellent 158 discrimination capacity of the cHIS score in our cohort¹³. In contrast to that study, 159 160 most of our patients (108/139, 78%) had received immunomodulatory or suppressive 161 therapies just before the laboratory evaluation (as part of our standard of care and based upon WHO guidelines and findings of the Recovery trial¹⁶). Dexamethasone 162 163 reduces CRS and improves the outcome while inevitably lowers the cHIS score¹⁶. The cHIS score is probably more appropriate to identify high-risk patients in ambulatory 164 practice or among the hypoxemic and dexamethasone-naïve patients. 165

166

167 Association of plasma zinc concentration and cHIS score

168 We were not able to show a significant association between plasma zinc levels and the

development of CRS (defined as cHIS score ≥ 2) in our cohort.

The mean concentration of plasma zinc was lower in patients with CRS compared to those without CRS (-5 μ g/dL; 95% CI, -10.5 to 0.051; *P* = 0.048). However, with stringent and conservative Bonferroni adjustment, the results were not statistically significant.

174

175 Discussion and limitations of the study

176 The small sample size and lack of a comparable control group (hospitalized for other

177 reasons than COVID-19) are the major limitations.

Additionally, as the absolute majority of the patients were zinc deficient, no room was
left for any comparison between zinc deficient and non-existing zinc sufficient
patients.

181

182 Conclusions

To the best of our knowledge, we report for the first time that an absolute majority ofhospitalized COVID-19 patients are zinc deficient.

185 We find a weak (reverse) correlation between plasma zinc concentration and the 186 length of hospital stay, but not with mortality or morbidity.

187 We independently validated cHIS as a score of COVID-19 severity, but we found no

188 significant association between zinc plasma concentration and cHIS among patients

189 who are almost all zinc deficient.

As such, our findings do not support the role of zinc as a robust prognostic factoramong hospitalized COVID-19 patients.

We recommend zinc to be measured prospectively in a larger, non-COVID-19 population to assess the incidence of the disease and CRS occurrence and its related outcomes in zinc-deficient versus zinc-sufficient individuals.

We encourage further studies to explore the role of zinc as a biomarker for assessing
the risk of developing a tissue-damaging CRS and predicting outcomes in patients
diagnosed with COVID-19.

198

199 Abbreviations

200	ARDS	Acute respiratory distress syndrome
201	AUROC	Area under the receiver operating characteristic curve
202	BMI	Body mass index
203	cHIS	COVID-19-associated hyperinflammatory syndrome

204	CI	Confidence interval
205	CRS	Cytokine release syndrome
206	ICU	Intensive care unit
207	IQR	Interquartile range
208	SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
209	SD	Standard deviation

210

211 Ethics approval and consent to participate

212 Informed consent was obtained from all participants. The study was approved by the

ethics committee of Erasme Hospital, EC identifier P2020/261.

214

215 Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

218

219 Conflict of interest and funding: We hereby confirm that there is no conflict of 220 interest associated with this publication and that this work did not receive any 221 financial support that could have influenced its outcome.

222

223 Author contributions

G.V and M.Noep: conceived the idea, co-authored the research proposal, designed the study, analyzed the data, interpreted the results, generated the tables, and coauthored the manuscript. G.V: medical consultation and handling the patients' material. M.Nop: supervised the study design and the statistical analyses and critically revised and contributed to drafting the manuscript. M.L, C.M, F.C: handled the patients' material and performed the laboratory assessments. C.G: contributed to

230 drafting the research proposal and study design. M.H. supervised all stages of the 231 study, including the proposal and the study design, and critically revised and 232 contributed to drafting the manuscript. All authors revised and approved the 233 manuscript. 234 Acknowledgments 235 Special thanks to Prof.Dr. Frédérique Jacobs (Université Libre de Bruxelles, Erasme 236 237 Hospital). 238 239 References 240 1. Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a 241 rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet. Respir. Med. 8, 1233-1244 (2020). 242 Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. & Sekhon, M. S. 243 2. 244 Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm 245 syndrome. Eur. Respir. J. 56, 2003006 (2020). 246 3. Read, S. A., Obeid, S., Ahlenstiel, C. & Ahlenstiel, G. The Role of Zinc in

247 Antiviral Immunity. *Adv. Nutr.* **10**, 696–710 (2019).

248 4. Boudreault, F. *et al.* Zinc deficiency primes the lung for ventilator-induced
249 injury. *JCI insight* 2, (2017).

5. Wessels, I. *et al.* Zinc supplementation ameliorates lung injury by reducing

neutrophil recruitment and activity. *Thorax* **75**, 253–261 (2020).

252 6. Asl, S. H., Nikfarjam, S., Majidi Zolbanin, N., Nassiri, R. & Jafari, R.

253 Immunopharmacological perspective on zinc in SARS-CoV-2 infection. *Int.*

254 *Immunopharmacol.* **96**, 107630 (2021).

255 7. Noeparast, A.; Verschelden, G.; Degeyter, D.; Marco, M.; Goyvaerts, C.; Hites,

256		M. In Light of the SARS-CoV-2 Pandemic: Revisit of the Evidence Associating
257		Zinc and Anti-viral Response. Preprints 2020, 2020040094. In Light of the
258		SARS-CoV-2 Pandemic: Revisit of the Evidence Associating Zinc and Anti-viral
259		Response. Preprints 2020040094 , (2020).
260	8.	Prasad, A. S. Zinc in human health: effect of zinc on immune cells. <i>Mol. Med.</i>
261		14 , 353–357 (2008).
262	9.	Prasad, A. S. et al. Zinc supplementation decreases incidence of infections in
263		the elderly: effect of zinc on generation of cytokines and oxidative stress. Am .
264		J. Clin. Nutr. 85 , 837–844 (2007).
265	10.	Mehta, P. et al. COVID-19: consider cytokine storm syndromes and
266		immunosuppression. Lancet (London, England) (2020) doi:10.1016/S0140-
267		6736(20)30628-0.
268	11.	Davies, I. J., Musa, M. & Dormandy, T. L. Measurements of plasma zinc. I. In
269		health and disease. J. Clin. Pathol. 21 , 359–363 (1968).
270	12.	A minimal common outcome measure set for COVID-19 clinical research.
271		Lancet. Infect. Dis. 20, e192–e197 (2020).
272	13.	Webb, B. J. et al. Clinical criteria for COVID-19-associated hyperinflammatory
273		syndrome: a cohort study. <i>Lancet. Rheumatol.</i> 2 , e754–e763 (2020).
274	14.	Hosmer, D. W. & Lemeshow, S. Applied Logistic Regression Second Edition.
275		Applied Logistic Regression (2004).
276	15.	YOUDEN, W. J. Index for rating diagnostic tests. <i>Cancer</i> 3 , 32–35 (1950).
277	16.	Horby, P. <i>et al.</i> Dexamethasone in Hospitalized Patients with Covid-19. <i>N</i> .
278		Engl. J. Med. 384 , 693–704 (2021).
279		

Table 1: Characteristics of study cohort (N=139)	No. Available	Value
Age (yr), median [IQR]	139	65 [54-77]
Gender - N (%)	139	
Female		48 (34)
Male		91 (65)
BMI (kg/m²), median [IQR]	135	27,2 [23-48]
Overweight (BMI≥25)		52 (38)
Obese (BMI≥30)		41 (30)
Smoking status, N (%)		
Never		97 (70)
Former		35 (25)
Current		7 (5)
Number of coexisting conditions, N (%)	139	
0		5(4)
1		19 (14)
2		19 (14)
>2		96 (69)
Uncertain Conditions, N (%)	139	aa(6 - 1)
Hypertension Dishetes		90 (65)
Diabeles		50(36)
Obstructive sleep appea syndrome		54 (39)
Obstructive lung diseases		11(0)
Coronary artery disease		$\frac{25(10)}{10(14)}$
Congestive heart failure		19 (14) 22 (16)
Atrial fibrillation		$\frac{2}{14}(10)$
Chronic liver disease		4 (2)
Chronic kidney disease		31 (22)
Malign neoplasm		9(6)
Immune suppression		25 (18)
Neurological nonvascular		12 (9)
Stroke		8 (6)
Days with symptoms before inclusion, median [IOR]	131	8[6-12]
Days of hospitalization before inclusion, median [IOR]	139	1[1-2]
COVID-19 medical therapy before inclusion	139	108 (78)
Hydroxychloroquine	0,7	9(6)
Dexamethasone		99 (71)
Severity of COVID-19 (worst WHO score)	139	<i>,,,,</i> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Median WHO score [IQR]	0,	4 [4-6]
With score >5 (severe disease), N (%)		42 (30)
cHIS score at inclusion	134	1- (0-5)
Median [IOR]	01	2 [1-2]
With cHIS score ≥ 2 , N (%)		74 (55)
Plasma zinc (Normal range: [80-120µg/dL])	139	, , (00)
Mean level (SD)	-07	56.2 (14.8)
With zinc deficiency, N (%)		133 (06)
		-00 (90)

Table 2a: Outcomes at 90-days (N=139)	Value			
Length of hospital stay (days), median [IQR]	8 [5-13]			
Mechanical ventilation, N (%)	42 (30)			
ICU admission, N (%)	19 (14)			
Deceased, N (%)	20 (14)			
Table 2b: Association of outcomes and plasma zinc level (N=139)	Value			
Lenght of hospital stay and zinc level	Correlation coefficien (95% CI) = -0.19 (-0.35-0.03), $p = 0.022^{**}$			
Mechanical ventilation and zinc level	OR (95% CI)= 0.98 (0.95-1.00), <i>p</i> =0.058***			
Mortality and zinc level	OR (95% CI)= 0.97 (0.94-1.00), <i>p</i> =0.065***			
Note:				
IQR = interquartile range, CI = confidence interval, OR = odds ratio				
**Spearman correlation				
*** Logistic regression				

